Targeted therapy can be used for non-small cell lung cancer (NSCLC) patients with gene sensitive mutations, such as EGFR or ALK mutations, especially for those with lung adenocarcinoma (LUAD), and the survival rate is significantly better than that of patients without sensitive mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.